Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-SNCA in Early Parkinson's Disease
NCT07216066Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Jun 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing ALN-SNCA Dose Escalation with Matching Placebo (2 arms). Primary endpoints: Occurrence of Treatment-Emergent Adverse Events at 80 weeks and Severity of Treatment-Emergent Adverse Events at 80 weeks. Started Dec 2025; status: recruiting.
02
Drugs
ALN-SNCA
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07216066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216066.